World Journal of Surgery

, Volume 36, Issue 3, pp 675–683

Partial Pathologic Response and Nodal Status as Most Significant Prognostic Factors for Advanced Rectal Cancer Treated With Preoperative Chemoradiotherapy

  • Marianne Huebner
  • Bruce G. Wolff
  • Thomas C. Smyrk
  • Jeremiah Aakre
  • David W. Larson
Article

Abstract

Background

This study evaluated the impact of tumor regression grading (TRG) and other pathologic variates in a cohort of rectal carcinoma patients treated with neoadjuvant chemoradiotherapy (CRT). The value of a grading less than pCR for predicting survival is unknown. Tumor budding has not been systematically studied in rectal cancer after neoadjuvant therapy.

Methods

Pathologic risk factors for survival were evaluated on surgical specimens of 237 patients with stages I, II, and III rectal cancer treated between 1996 and 2006. All patients underwent preoperative CRT followed by surgical resection 6–8 weeks later. TRG, tumor grade, budding, venous invasion, radial margin, and nodal status were evaluated. The prognostic value of TRG categories was calculated with Cox regression models and validated with resampling methods.

Results

TRG of <25% occurred in 61 (25.7%) and a complete response in 39 (16.4%) of the resected specimens. TRG of <25% was shown to be a statistically significant predictor for cancer-specific survival (CSS) and recurrence-free survival (RFS) compared to TRG ≥25% (P = 0.013). Tumor budding was present in 24 (10.1%) of the patients and was negatively associated with CSS (P = 0.013). Lymph node involvement was observed in 83 (35.0%) patients. TRG and nodal status (P < 0.001) were the most significant predictors associated with outcome.

Conclusion

Partial pathologic response ≥25% was a superior predictor compared to pCR for improved survival after preoperative CRT. CSS and RFS were adversely affected by the presence of lymph node metastases.

References

  1. 1.
    Anonymous (2010) AJCC cancer staging manual. In: Edge SB, Byrd DR, Compton CC et al (eds) Colon and Rectum. Springer, New YorkGoogle Scholar
  2. 2.
    Kim TH, Chang HJ, Kim DY et al (2010) Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Int J Radiat Oncol Biol Phys 77:1158–1165PubMedCrossRefGoogle Scholar
  3. 3.
    Roh MS, Colangelo LH, O’Connell MJ et al (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27:5124–5130PubMedCrossRefGoogle Scholar
  4. 4.
    Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRefGoogle Scholar
  5. 5.
    Capirci C, Valentini V, Cionini L et al (2008) Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 72:99–107PubMedCrossRefGoogle Scholar
  6. 6.
    Kalady MF, de Campos-Lobato LF, Stocchi L et al (2009) Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 250:582–589PubMedGoogle Scholar
  7. 7.
    Smith KD, Tan D, Das P et al (2010) Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg 251:261–264PubMedCrossRefGoogle Scholar
  8. 8.
    Rodel C, Martus P, Papadoupolos T et al (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8696PubMedCrossRefGoogle Scholar
  9. 9.
    Okuyama T, Oya M, Ishikawa H (2003) Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma. J Surg Oncol 83:42–47PubMedCrossRefGoogle Scholar
  10. 10.
    Ueno H, Price AB, Wilkinson KH et al (2004) A new prognostic staging system for rectal cancer. Ann Surg 240:832–839PubMedCrossRefGoogle Scholar
  11. 11.
    Bouzourene H, Bosman FT, Seelentag W et al (2002) Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 94:1121–1130PubMedCrossRefGoogle Scholar
  12. 12.
    Suarez J, Vera R, Balen E et al (2008) Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. Colorectal Dis 10:563–568PubMedCrossRefGoogle Scholar
  13. 13.
    Losi L, Luppi G, Gavioli M et al (2006) Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy. Int J Colorectal Dis 21:645–651PubMedCrossRefGoogle Scholar
  14. 14.
    Vecchio FM, Valentini V, Minsky BD et al (2005) The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 62:752–760PubMedCrossRefGoogle Scholar
  15. 15.
    Zaheer S, Pemberton JH, Farouk R et al (1998) Surgical treatment of adenocarcinoma of the rectum. Ann Surg 227:800–811PubMedCrossRefGoogle Scholar
  16. 16.
    Ueno H, Murphy J, Jass JR et al (2002) Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 40:127–132PubMedCrossRefGoogle Scholar
  17. 17.
    Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19–23PubMedCrossRefGoogle Scholar
  18. 18.
    Harrell F, Lee KL, Califf RM et al (2006) Regression modelling strategies for improved prognostic prediction. Stat Med 3:143–152CrossRefGoogle Scholar
  19. 19.
    R Development Core Team (2009) R: a language and environment for statistical computing. R Foundation for Statistical Computing, ViennaGoogle Scholar
  20. 20.
    Nagtegaal I, Marijnen C (2008) The future of TNM staging in rectal cancer: the era of neoadjuvant therapy. Curr Colorectal Cancer Rep 4:147–154CrossRefGoogle Scholar
  21. 21.
    Beddy D, Hyland JM, Winter DC et al (2008) A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol 15:3471–3477PubMedCrossRefGoogle Scholar
  22. 22.
    Bujko K, Kolodziejczyk M, Nasierowska-Guttmejer A et al (2010) Tumour regression grading in patients with residual rectal cancer after preoperative chemoradiation. Radiother Oncol 95:298–302PubMedCrossRefGoogle Scholar
  23. 23.
    Hase K, Shatney C, Johnson D et al (1993) Prognostic value of tumor “budding” in patients with colorectal cancer. Dis Colon Rectum 36:627–635PubMedCrossRefGoogle Scholar
  24. 24.
    Jass JR, O’Brien J, Riddell RH et al (2008) Recommendations for the reporting of surgically resected specimens of colorectal carcinoma: Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol 129:13–23PubMedCrossRefGoogle Scholar
  25. 25.
    Masaki T, Matsuoka H, Sugiyama M et al (2006) Actual number of tumor budding as a new tool for the individualization of treatment of T1 colorectal carcinomas. J Gastroenterol Hepatol 21:1115–1121PubMedCrossRefGoogle Scholar
  26. 26.
    Wang LM, Kevans D, Mulcahy H et al (2009) Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 33:134–141PubMedCrossRefGoogle Scholar
  27. 27.
    Prall F (2007) Tumour budding in colorectal carcinoma. Histopathology 50:151–162PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2012

Authors and Affiliations

  • Marianne Huebner
    • 1
    • 2
  • Bruce G. Wolff
    • 3
  • Thomas C. Smyrk
    • 4
  • Jeremiah Aakre
    • 1
  • David W. Larson
    • 3
  1. 1.Division of Health Sciences ResearchMayo ClinicRochesterUSA
  2. 2.Department of Statistics and ProbabilityMichigan State UniversityEast LansingUSA
  3. 3.Division of Colorectal Surgery, Department of SurgeryMayo ClinicRochesterUSA
  4. 4.Department of Laboratory Medicine and PathologyMayo ClinicRochesterUSA

Personalised recommendations